Asitri Dashboard

Search Clinical Trials

The U.S. National Library of Medicine provides a database of clinical trials worldwide. Use the fields below to search the database. Expand your results and select terms or phrases and right-click to search using Google, MalaCards, MedlinePlus, PubMed, or Wikipedia.

Saved Searches

Choose Search
Basic Search
Targeted Search

Clinical Trials Search Results

Query: "AREA[SponsorSearch](Point Therapeutics)"
Count: 18
Selected: 0
NCT IDTitle
NCT00290017Study of Talabostat and Pemetrexed vs. Pemetrexed in Stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC) After Failure of Platinum-Based Chemotherapy
NCT00243204Study of Talabostat + Docetaxel Versus Docetaxel in Stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC) After Failure of Platinum-Based Chemotherapy
NCT00116389Trial of Talabostat and Gemcitabine in Patients With Stage IV Adenocarcinoma of the Pancreas
NCT00083252Study of Talabostat and Cisplatin in Advanced Melanoma
NCT00083239Study of Talabostat in Advanced Melanoma
NCT00080080Study of Talabostat and Docetaxel in Advanced Non-Small Cell Lung Cancer
NCT05828303A Phase 1 Study to Evaluate the Potential Drug Interactions Between Repotrectinib and Metformin, Digoxin, and Rosuvastatin in Patients With Advanced Solid Tumors
NCT05828277A Phase 1 Study to Assess the Effect of Hepatic Impairment on the Pharmacokinetics of Repotrectinib in Advanced Cancer Patients
NCT05071183A Study of Repotrectinib in Combination With Other Anticancer Therapies for the Treatment of Subjects With KRAS-Mutant Solid Tumors
NCT05001516Study of Turning Point Therapeutics LM-302 in Patients With Advance Solid Tumors
NCT04849273A Study of TPX-0131, a Novel Oral ALK Tyrosine Kinase Inhibitor, in Patients With ALK+ Advanced or Metastatic NSCLC
NCT04161391Study of TPX-0046, A RET/SRC Inhibitor in Adult Subjects With Advanced Solid Tumors Harboring RET Fusions or Mutations
NCT04094610A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations
NCT03993873Study of TPX-0022 in Patients With Advanced NSCLC, Gastric Cancer or Solid Tumors Harboring Genetic Alterations in MET
NCT03093116A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements
NCT00086203Study of Talabostat and Rituximab in Advanced Chronic Lymphocytic Leukemia (CLL)
NCT04772235Phase I Study of Repotrectinib and Osimertinib in NSCLC Patients
NCT04026750Insulin Tolerance Test Study in Patients With Type 1 Diabetes